First of all, it's difficult to agree on what are first-in-class drugs. One of the ways we've tried to analyze this is that manufacturers can submit to us a drug for priority review on clinical grounds. A drug that the manufacturer believes to be available to treat a very serious or life-threatening condition, for which no other treatment is available in Canada, you could consider to be a first-in-class drug.
When we've looked at those drugs that we've reviewed and the percentage of those that have received a positive recommendation, it's about the same for all of the other drugs. It's around 50%. So we don't believe there's a difference in how we review those drugs that get priority review.